Background. In human immunodeficiency virus (HIV)-infected patients on combination antiretroviral therapy (cART), lipodystrophy shares many similarities with metabolic syndrome, but only metabolic syndrome has objective classification criteria. We examined adipose tissue changes related to lipodystrophy and metabolic syndrome to clarify whether it may be acceptable to focus diagnosis on metabolic syndrome rather than lipodystrophy.
Lipodystrophy is a pathological adipose tissue redistribution syndrome that exists in 3 phenotypes: lipoatrophy, lipohypertrophy, and mixed type lipodystrophy [1, 2] . Both antiretroviral treatment and human immunodeficiency virus (HIV)-infection itself induce cellular and molecular changes in adipose tissue. Thymidine nucleoside reverse-transcriptase inhibitors (NRTIs) were shown to induce lipoatrophy in multiple studies, whereas the etiology of lipohypertrophy is not clear [3] [4] [5] [6] [7] . With newer nonthymidine NRTI combination antiretroviral therapy (cART), lipodystrophy may primarily manifest as lipohypertrophy.
Lipodystrophy shares many cardiometabolic risk factors with metabolic syndrome, including central adiposity, hyperlipidemia, increased systemic inflammation, impaired glucose tolerance, and elevated blood pressure [2, 8, 9] . Metabolic syndrome is also highly prevalent in HIV-infected patients on cART [10] . Both lipodystrophy and metabolic syndrome are characterized by local changes in adipose tissue. These changes include increased expression of inflammation markers such as interleukin-6 (IL-6), C-X-C motif chemokine ligand 10 (CXCL10), and C-C motif chemokine ligand 2 (CCL2) messenger ribonucleic acid (mRNA) expression, which contribute to the infiltration of immune cells, as well as decreased expression of genes related to adipose tissue function; although with some contrasting results [1, [11] [12] [13] [14] [15] . Well functioning, objective, classification criteria exist for metabolic syndrome diagnosis; however, lipodystrophy has no validated definition [11] . Therefore, it may be beneficial to assess cardiometabolic risk in HIV-infected patients based on metabolic syndrome diagnosis and direct interventions towards metabolic syndrome, rather than lipodystrophy M A J O R A R T I C L E [16] . To our knowledge, no studies have investigated local adipose tissue changes related to metabolic syndrome in HIVinfected patients with and without lipodystrophy. Therefore, it remains unknown whether metabolic syndrome and lipodystrophy are characterized by similar unfavorable local adipose tissue changes in HIV-infected patients, and whether interventions to reduce cardiometabolic risk can be based on metabolic syndrome alone.
Adipose tissue structure, integrity, and function are regulated by a network of transcription factors with peroxisome-proliferator-activated receptor (PPAR)-γ, sterol regulatory element-binding protein (SREBP), and CCAAT enhancer-binding protein-α being central. The expression of these transcription factors is decreased in HIV infection and lipodystrophy [17, 18] . Expression of genes involved in fatty acid metabolism such as lipoprotein lipase (LPL) is also decreased in lipodystrophy [17] . In recent years, other factors such as sirtuin 1 (SIRT1), fibroblast growth factor 2 (FGF-2), mammalian target of rapamycin (mTOR), and forkhead box protein O1 (FOXO1) have been shown to affect adipose tissue function and inflammation [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . However, it is not known whether these factors are implicated in adipose tissue dysfunction in HIV-infected patients.
The aims of this study were (1) to determine whether lipodystrophy and metabolic syndrome are characterized by similar unfavorable changes in abdominal subcutaneous adipose tissue (SAT) and (2) to assess the changes attributed to HIV/ cART. We evaluated abdominal SAT structure (histology), function (adiponectin, leptin, FGF-2, PPAR-γ, SREBP, LPL, SIRT1, FOXO1, and mTOR mRNA expression), and inflammation (IL-6, CCL2, CXCL10 mRNA expression) in well treated HIV-infected patients on newer cART and in healthy controls. We assessed the effects of (1) HIV/cART by comparing HIVinfected patients and controls, (2) lipodystrophy by comparing HIV-infected patients with and without lipodystrophy, and (3) metabolic syndrome by comparing HIV-infected patients with and without metabolic syndrome. We hypothesized that unfavorable abdominal SAT alterations could underlie adipose tissue dysfunction and risk of cardiometabolic complications in lipodystrophy and metabolic syndrome.
METHODS

Study Design
The HIV-infection and Fat Inflammation (Hi-Fi) study was designed as a cross-sectional study to detect a doubling of abdominal SAT macrophage infiltration with a power of 93%, a standard deviation (SD) of 0.005 from [12] , and a significance level of 0.05 between HIV-infected patients with and without lipodystrophy. This gave 30 HIV-infected patients with lipodystrophy and 30 without. The sample size for healthy men (controls) and cART-naive HIV-infected patients were based on Giralt et al [5] . Other results from the Hi-Fi study have been published previously [31] [32] [33] .
Ethics
The local ethics committee of the Capital Region of Denmark (Journal number H-4-2010-045) and the Danish Data protection agency (Project number 2010-41-4952) approved the study. The study was carried out according to the declaration of Helsinki. Oral and written informed consent was obtained from all participants.
Subjects
From November 2010 to October 2012, we included HIVinfected patients from the Out Patients' Clinic at the Department of Infectious Diseases, Copenhagen University Hospital Hvidovre, and healthy controls of similar age via advertisement at the hospital. Inclusion criteria were as follows: male sex; ≥18 years; white ethnicity; no current hepatitis B or C (and HIV for controls), immunomodulating treatment or disease, lipid-lowering, antidiabetic, or endocrinological treatment; no intravenous drug use. Combination antiretroviral therapy-treated HIV-infected patients had to fulfill the following: ≥12 month on cART, CD4 + cell counts ≥200 cells/µL, and HIV-RNA <400 copies/mL.
Study Protocol
Smoking was assessed by a self-administered questionnaire. Anthropometry was carried out as by Andersen et al [34] and included the following: body weight, height, resting blood pressure, and waist circumference. Fasting blood samples were obtained for measurements of lipids, glucose, and insulin using standard procedures. Insulin sensitivity was assessed using homeostasis model assessment (HOMA-IR) [35] . Metabolic syndrome was assessed according to the JIS-2009 consensus definition, using ≥94 cm as waist circumference cutoff, as recommended for high-risk populations [11] .
A radiologist evaluated abdominal SAT as "SAT area (cm 2 )" and abdominal visceral adipose tissue (VAT) as "VAT area (cm 2 )" by single-slice computed tomography (CT) scan (Somatom Sensation 10; Siemens) at the upper limit of L4, as previously done by Hansen et al [36] . Total fat mass was evaluated by Dual energy X-ray absorptiometry (DXA) scan (Norland XR-36; Gammatec A/S, Vaerløse, Denmark). Fat mass index was evaluated as follows: total fat mass/height 2 (kg/m 2 ) [37] .
Lipodystrophy was determined by physical examination of lipoatrophy and lipohypertrophy in the face, retroauricular region, dorsocervical region, upper arms, thighs, buttocks, and abdominal subcutaneous and visceral regions. Patients without signs of lipoatrophy or lipohypertrophy were characterized as non-lipodystrophic. If only abdominal lipohypertrophy was present, patients were also characterized as non-lipodystrophic. Patients were characterized with lipodystrophy if they had the following: ≥1 anatomical site of lipoatrophy (lipoatrophic), ≥1 anatomical site of lipohypertrophy (lipohypertrophic), and/or ≥1 anatomical site of lipoatrophy and ≥1 anatomical site of lipohypertrophy (mixed type), as previously described by Andersen et al [34] .
Abdominal SAT biopsies were obtained periumbilically by needle aspiration using aseptic technique and local anesthesia in the morning after an overnight fast. One part of the biopsy was formalin-fixed overnight, the other part was snap frozen in liquid nitrogen and stored at −80°C. We assessed inflammation marker levels in the interstitial fluid of abdominal SAT obtained from patients and controls using microdialysis (Supplementary Data 1) .
Immunohistochemical Analyses and Automated Quantification by Digital
Image Analysis
Formalin-fixed, paraffin-embedded biopsies were sectioned (4-µm thick) and de-paraffinized in Tissue clear (Dako, Glostrup, Denmark). Sections were processed in a Dako Autostainer (Dako) with antibodies targeting macrophages (monoclonal mouse anti-human CD68, Clone PG-M1, code IR613; Dako), T cells (polyclonal rabbit anti-human CD3, code: IR503, Dako), and B cells (monoclonal mouse anti-human CD20cy, clone L26, code IR604; Dako) and visualized with 3,3-diaminobenzidine (Dako). Sections were counterstained with Meyer's hematoxylin, dehydrated, mounted on coated slides, and dried. Negative and positive controls were included for all staining procedures.
Positively stained cells were counted by a pathologist (blinded for clinical information) in 10 high-power fields (HPFs) at ×400 magnification (manual scoring). In sections comprising less than 10 HPFs (5 subjects: 3 patients with lipodystrophy and 2 controls), positively stained cells were counted in the available HPFs (5-7 HPFs).
CD68 + cell morphology was highly variable, as seen in Supplementary Figure 2 . Macrophages arranged in crown-like structures were counted in the biopsy sections because these macrophage structures could impact adipose tissue health [13, 17, 38] Stained whole slides were captured and digitalized at ×20 magnification using the Hamamatsu Nanozoomer 2.0HT (Hamamamatsu Photonics, Hamamamatsu City, Japan). Virtual slides were analyzed using Visiopharm Integrator System, version 4.4.4.0 (Visiopharm, Hørsholm, Denmark). Adipose tissue morphology was assessed in hematoxylin and eosin (HE)-slides by the Visiomorph DP module. An analysis protocol package was designed to detect cytoplasmic strings and stroma in digitalized HE-slides. The analysis protocol package identified and classified regular lipid vacuoles surrounded by stroma and cytoplasma as adipocytes. The area of each adipocyte vacuole in the classified image was automatically measured, and the mean vacuole area in the entire slide was calculated as the mean adipocyte size (Supplementary Figure 2J -L). Another analysis protocol package was designed to estimate the CD68 + and CD3 + area fractions in immunohistochemical slides (automated scoring) using the Tissuemorph DP module (Supplementary Figure 2K -M). The CD20 + area fraction was not evaluated due to the low numbers of CD20 + cells. All virtual slides were screened visually to ensure correct and satisfactory classification within each slide after completed automated quantification.
Gene Expression Analyses
Snap-frozen biopsies were homogenized for 20 seconds at 4600 rpm using Magnalyzer Beads (catalog no. 03358941001; Roche, Basel, Switzerland) in QIAzol (QIAGEN) with the Magnalyzer (Roche). Ribonucleic acid was extracted from homogenates using chloroform (catalog no. C2432-500ML; Sigma-Aldrich), RNeasy Lipid Tissue Mini kit (catalog no. 74804; QIAGEN, Hilden, Germany), and DNAse treatment (catalog no. 79254; QIAGEN), following the manufacturer's instructions. Ribonucleic acid concentration was measured on a Nanodrop (ThermoFisher Scientific). Ribonucleic acid quality was checked with QIAxcel RNA Quality Control Kit (catalog no. 929104; QIAGEN) with a mean RNA Integrity Number number of 7.6. Ribonucleic acid was converted to complementary deoxyribonucleic acid (DNA) with a standard input of 0.273 ng of RNA using the QuantiNova Reverse Transcription Kit (catalog no. 20541; QIAGEN) following the manufacturer's instructions.
We We titrated primer and probe concentrations, ensured specificity by agarose gel electrophoresis, tested amplification from genomic DNA by including a no reverse transcriptase control, and tested the efficiency for all polymerase chain reactions (PCRs), which was between 1.86 and 2.15. The PCR quality for CXCL10, SIRT1, and FOXO1 was not satisfactory; therefore, we used RealTime Ready probe and primer mix (FOXO1 assay ID 137191; CXCL10 assay ID 103807; SIRT1 assay ID 102150; Roche) for these genes. Gene transcripts were amplified in duplicates using LightCycler 480 Probes Master (product no. 04887301001; Roche) in a LightCycler 480 (catalog no. 04887301001; Roche) for 45 cycles with 10 seconds preincubation at 95°C and amplification for 10 seconds at 95°C, 30 seconds at 60°C, and 1 second at 72°C. Gene expression was normalized by subtracting the C t from the gene of interest from the C t from the geometric mean of the 3 reference genes.
Statistics
Differences in baseline characteristics between controls and patients without lipodystrophy and between patients with and patients without lipodystrophy were analyzed using one-way analysis of variance (ANOVA) with post hoc Dunnett test for continuous variables. If residuals were not normally distributed, we used Wilcoxon analyses. Group differences in categorical variables were analyzed by χ 2 or Fisher's exact test if <5 individuals were expected in a group.
Due to the design of the Hi-Fi study, we first assessed the effect of HIV/cART on abdominal SAT structure and function by comparing patients without lipodystrophy and controls, and we assessed the effect of lipodystrophy by comparing patients with and patients without lipodystrophy using one-way ANOVA with post hoc Dunnett test for continuous variables or logistic regression for categorical variables. We then assessed the independent effects of lipodystrophy and of metabolic syndrome on abdominal SAT structure and function of HIV-infected patients using twoway ANOVA with lipodystrophy and metabolic syndrome as main effects or adjusted logistic regression. We investigated goodness of fit of the regression models for normal distribution of residuals and homogeneity of variance. If residuals were normally distributed, results are shown as mean and SD for each group and P value for mean difference. If residuals were not normally distributed, data were transformed using log2(×) to obtain normal distributed residuals, and estimates were back-transformed using 2 β -1. Results are shown as both median and interquartile range (IQR) for each group, and back-transformed estimate representing the percentage change in the outcome between the groups, and P value. For logistic regressions, odds ratios (OR) are shown. P values less than .05 were considered statistically significant. The statistics program SAS (version 9.3; SAS Institute, Cary, NC) was applied for analyses.
RESULTS
We included 60 HIV-infected patients on cART: 24 with lipodystrophy and 36 without lipodystrophy; 3 naive to cART (excluded due to low sample size); and 16 controls (1 control was excluded due to recent hip surgery) (Supplementary Figure 3) .
Baseline Characteristics
Baseline characteristics for the study participants are shown in Table 1 . Patients with lipodystrophy had higher age (P = .02), abdominal VAT (P = .04), and ratio of abdominal VAT to abdominal SAT (P < .001) than patients without lipodystrophy. Patients with lipodystrophy also had longer HIV infection (P < .001) and cART (P < .001) durations and a higher proportion of patients previously treated with thymidine NRTI (P < .001) than patients without lipodystrophy. Patients without lipodystrophy had a higher HOMA-IR than controls (P = .046) and fewer CD4 + T cells (P = .03). Overall, HIVinfected patients had elevated abdominal VAT to abdominal SAT ratio (P = .02), HOMA-IR (P = .02), and a higher prevalence of metabolic syndrome (P = .04) compared with controls. 19) between patients with lipodystrophy and patients without, and this was unchanged when adjusting for metabolic syndrome status (adipocyte area: P = .75; manual scoring: 9.5% increase, P = .67; automated scoring: 40.4% increase, P = .16). a Differences between the groups were analysed using one-way ANOVA with post hoc Dunnett test.
Histological Changes Related to Human
b P < .05 for the comparison between patients with lipodystrophy and patients without lipodystrophy.
c Differences between the groups were analyzed using χ 2 or Fisher's exact test if <5 individuals were expected in a group.
d Differences between the groups were analysed using Wilcoxon test. Human immunodeficiency virus-infected patients without lipodystrophy had higher CXCL10 mRNA levels (P = .05) than controls and a trend towards increased CCL2 (P = .092) levels.
Patients with lipodystrophy had higher ADIPOQ mRNA levels than patients without (P = .05) ( Table 2) , and the effect did not change when adjusting for metabolic syndrome status (P = .01) ( Table 2 ). There were no other differences in the expression of genes related to adipose tissue function or inflammation between patients with and without lipodystrophy ( Table 2) .
Patients with metabolic syndrome had lower mRNA levels of genes related to adipose tissue function: ADIPOQ (P = .007), FGF2 (P = .033), PPARG (P = .008), LPL (P < .0001), SIRT1 (P = .015), and MTOR (P = .041), and higher LEP mRNA expression (P = .038) than patients without metabolic syndrome (Table 2) , and this effect was independent of lipodystrophy. We also found a trend towards decreased SREBP (P = .077) and FOXO1 (P = .078) mRNA expression and towards increased mRNA expression of genes related to inflammation: IL6 (P = .082) and CCL2 (P = .097), in patients with metabolic syndrome compared with patients without.
DISCUSSION
Lipodystrophy was only associated with increased abdominal SAT macrophage infiltration and ADIPOQ mRNA, whereas Abbreviations: ANOVA, analysis of variance; cART, combination antiretroviral therapy; HIV, human immunodeficiency virus; SAT, subcutaneous adipose tissue.
The expression of the genes of interest was normalized to the expression of 3 reference genes (ACTB, POLR2A, and 18s rRNA) and is shown as the mean Δc t = c t geometric mean of reference genes -c t gene of interest. The mean c t geometric mean of reference genes were as follows: controls = 21.1; no lipodystrophy = 20.8; lipodystrophy = 21.1; no metabolic syndrome = 20.9; metabolic syndrome = 20.9.
NOTES: The effects of HIV-infection and lipodystrophy on abdominal SAT were investigated using one-way ANOVA with post hoc Dunnett test comparing controls or patients with lipodystrophy to patients without lipodystrophy. The independent effects of lipodystrophy and metabolic syndrome on abdominal SAT were investigated using two-way ANOVA comparing patients with lipodystrophy to patients without and comparing patients with metabolic syndrome to patients without. Significant P values are in bold.
a P < .05 for the comparison between patients with lipodystrophy and patients without lipodystrophy in one-way ANOVA with post hoc Dunnett test and in two-way ANOVA.
b P < .05 for the comparison between patients without metabolic syndrome and patients with metabolic syndrome in two-way ANOVA.
c P < .05 for the comparison between patients without lipodystrophy and controls in one-way ANOVA with post hoc Dunnett test.
metabolic syndrome was associated with larger adipocytes, decreased expression of genes related to adipose tissue function, and there was a trend towards increased expression of genes related to inflammation. Moreover, the effect of metabolic syndrome appeared to be independent of lipodystrophy. To our knowledge, this is the first study to objectively evaluate adipocyte size in sections of abdominal SAT from HIVinfected patients. Adipocytes in patients with metabolic syndrome were larger than in patients without, whereas there was no effect of lipodystrophy. In the general population, enlarged adipocytes precede insulin resistance and could therefore be part of the mechanism that underlies cardiometabolic complications in HIV-infected patients [39] [40] [41] [42] . In addition, the expression of genes related to adipose tissue function was decreased in patients with metabolic syndrome compared with patients without. Decreased PPARG levels could result in decreased adipogenesis, thereby increasing adipocyte size and ectopic fat accumulation, and this could be further aggravated by decreased LPL. Moreover, the expression of FGF2, SIRT1, and MTOR was lower in patients with metabolic syndrome than in patients without. Fibroblast growth factor-2, SIRT1, and mTOR could thus be involved in adipose tissue dysfunction in metabolic syndrome in addition to the more well known factors adiponectin, leptin, PPAR-γ, and LPL. In contrast to previous studies [5, 43] , ADIPOQ expression was increased in lipodystrophy. Adiponectin expression is inversely related to fat mass, and this could reflect the low amount of SAT and the relatively preserved function of adipose tissue in patients with lipodystrophy in our study.
In agreement with findings from other studies, there was a trend towards both lipodystrophy and metabolic syndrome being independently associated with increased macrophage infiltration [12] [13] [14] . The function of abdominal SAT-infiltrating macrophages in HIV-infected patients is not established. We did not evaluate whether abdominal SAT-infiltrating macrophages were proinflammatory as reported in obesity [44] [45] [46] . However, there was a trend towards increased IL6 and CCL2 mRNA levels in patients with metabolic syndrome. Macrophages might have distinct functions in lipodystrophy and metabolic syndrome, because there were more crown-like structures in patients with metabolic syndrome compared with patients without and fewer crown-like structures in patients with lipodystrophy compared with patients without. However, the function of crown-like structures is not well established because there is no commonly accepted definition of crown-like structures in scientific papers.
There were no effects of HIV-infection, lipodystrophy, or metabolic syndrome on abdominal SAT T-cell infiltration. This is in contrast to findings in lipodystrophy and obesity [47, 48] . We did not further characterize abdominal SAT-infiltrating T cells, but both CD4 + and CD8 + T cells infiltrate abdominal SAT in obesity and in HIV infection [47, 48] . B-cell infiltration was in general very limited, supported by recently published results [49] .
There are some limitations to this study. We could not separate effects of HIV infection and cART on the differences between HIV-infected patients and controls. We also could not assess whether metabolic syndrome-associated changes were similar in HIV-infected patients and in the general population, because we included too few controls. Moreover, we could not separate the effects of lipodystrophy subtypes from metabolic syndrome, because 12 of 14 patient with lipohypertrophy or mixed type lipodystrophy had metabolic syndrome, and only 1 of 10 patients with lipoatrophy had metabolic syndrome. However, for patients with lipohypertrophy or mixed type lipodystrophy, this is difficult to circumvent. Our inclusion criteria were no antidiabetic or lipid-lowering treatment and therefore only included patients that were least likely to have metabolic syndrome. Despite this, HOMA-IR was higher in HIV-infected patients compared with controls, and 86% of patients with lipohypertrophy or mixed type lipodystrophy had metabolic syndrome. This may further support that with newer cART, it may be acceptable to focus on diagnosing metabolic syndrome rather than lipodystrophy.
CONCLUSIONS
In conclusion, metabolic syndrome rather than lipodystrophy was associated with major unfavorable local abdominal SAT changes, except for macrophage infiltration. Adipocytes were larger in HIV-infected patients with metabolic syndrome than in those without, and the expression of genes related to adipose tissue function was decreased. The effect of metabolic syndrome on abdominal SAT appeared to be independent of lipodystrophy.
Our findings add to the previously reported unfavorable systemic and anthropometric changes that lipohypertrophy and metabolic syndrome share. Therefore, it may be more relevant to assess and direct interventions towards metabolic syndrome in HIV-infected patients on newer cART with regards to adipose tissue dysfunction and risk of cardiometabolic complications.
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